In complete remission, all of the following cell subpopulations collected from peripheral blood (i.e., CD56+ NK cells, CD19+ B lymphocytes, CD14+ monocytes, CD66+ granulocytes, CD34+ CD45 - low blasts), and (i.e., CD34+ CD38− CD123+ and aldehyde dehydrogenase (ALDH) intermediate leukemic stem cells (LSCs) or CD34+ CD38− CD123+ and ALDH high hematopoietic stem cells (HSCs)) isolated from bone marrow harbored DNMT3A mutations but none of the molecular abnormalities (i.e., NPM1, IDH1/2 and FLT3-ITD mutations) identified at AML diagnosis. The gene discussed is CD19; the disease is acute myeloid leukemia.